SBASSE Biology Talk 2017
The mechanisms of actions of relaxin in the human cardiovascular
Guest Speaker: Dr. Mohsin Sarwar
Date: Wednesday, March 15, 2017
Time: 3:30 pm – 4:30 pm
Venue: Smart Room, 5th Floor, SBASSE Building
Host: Dr. Syed Shahzad Ul Hussan
Abstract
The phase III clinical trial, RELAX-AHF, demonstrated that 48 hour infusion of serelaxin, (recombinant hormone H2 relaxin) improved short and long term clinical outcomes in patients with acute heart failure (Teerlink et al. 2013). A likely target of relaxin in humans is the vasculature because relaxin has potent vasodilatory effects in vivo (McGuane et al. 2011) and in patients with AHF (Ponikowski et al. 2013). As such, we characterised the signal transduction mechanisms of relaxin in human primary vascular cells (endothelial, smooth muscle and fibroblast) to better understand the mechanisms governing relaxin’s vasodilatory effects.
Profile
Dr. Mohsin Sarwar began his research career in 2008 when he completed his Bachelors in Medical Science from Monash University (Australia). He was awarded a Special Departmental Scholarship, and he accepted a challenging PhD project in the laboratory of Prof. Roger Summers. After completing his PhD in 2015, he was offered a Research Fellow position in the laboratory of Dr. Christopher Langmead where he is currently working on a range of different drug discovery projects in collaboration with the French Pharmaceutical company, Servier Laboratories.
